Edwards Lifesciences CORP Form 4 insider transactions

CFO Scott B. Ullem disposed of 3,034 shares of Edwards Lifesciences common stock to cover tax obligations.

Director Leslie C. Davis was granted 3,251 restricted stock units by Edwards Lifesciences Corporation.

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, received restricted stock units and stock options as part of the company's long-term incentive program.

SVP and Corporate Controller Andrew M. Dahl received restricted stock units and stock options as part of the company's long-term incentive program.

Edwards Lifesciences CVP Daveen Chopra received equity-based compensation including stock options and restricted stock units.

Annette Bruls, CVP of EMEACLA at Edwards Lifesciences, received equity-based compensation including restricted stock units and options.

CFO Scott B. Ullem exercised 13,000 stock options and conducted related tax withholding transactions in early May 2026.

CEO Bernard J. Zovighian reported routine changes in beneficial ownership of Edwards Lifesciences common stock.

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, executed stock option exercises and sales under a 10b5-1 plan.

Daveen Chopra, CVP of TMTT & Surgical at Edwards Lifesciences, reported the disposition of 282 shares of common stock.

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences, reported a routine disposition of shares to cover tax obligations.

Edwards Lifesciences CFO Scott B. Ullem reports transactions involving common stock, including purchases and sales executed under a Rule 10b5-1 trading plan.

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, exercised options and sold 1,019 shares under a pre-arranged trading plan.

Donald E. Bobo Jr., VP of Strategy and Corporate Development at Edwards Lifesciences, executed a series of stock transactions under a pre-arranged trading plan.

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, executed a pre-planned sale of 11,340 common shares following an option exercise.

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, reported the sale of 24,000 common shares and a correction in beneficial ownership.

Edwards Lifesciences CVP Daniel J. Lippis reported the disposition of 432 common shares at $79.78 each for tax withholding purposes.

Edwards Lifesciences SVP, Corporate Controller Andrew M. Dahl disposed of 176 shares of common stock to cover tax liabilities.

Edwards Lifesciences CEO Bernard J. Zovighian reported the exercise of stock options and subsequent sale of common stock, alongside a gift of shares, on February 12-13, 2026.

Edwards Lifesciences CVP Daniel J. Lippis sold 1,019 shares of common stock for $85.7037 per share, following an option exercise, under a pre-arranged 10b5-1 trading plan.

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, executed pre-planned stock option exercises and sales.

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, reported sales and a gift of common stock totaling 18,486.1175 shares on December 12, 2025.

Edwards Lifesciences CVP Daniel J. Lippis sold 1,019 shares of common stock for $84.03 per share after exercising options, as part of a pre-arranged 10b5-1 trading plan.

Edwards Lifesciences Director Leslie Stone Heisz reported the sale of 2,615 shares of common stock for approximately $218,000 on December 12, 2025.

Daveen Chopra, CVP of TMTT & Surgical at Edwards Lifesciences, sold 2,000 shares of common stock for $84.3751 per share.

Edwards Lifesciences CVP Donald E. Bobo Jr. exercised options and sold 11,340 shares of common stock under a pre-arranged 10b5-1 trading plan.

Edwards Lifesciences CEO Bernard J. Zovighian exercised stock options and sold a portion of his common stock holdings in pre-planned transactions.

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and sold 7,700 shares of common stock under a pre-arranged trading plan.

Edwards Lifesciences CVP Wayne Markowitz reported the sale of 583 common shares for $86.01 each under a pre-arranged trading plan.

Edwards Lifesciences' SVP, Corporate Controller Andrew M. Dahl, was granted 1,160 restricted stock units and acquired shares through an employee stock purchase plan.